

Chronic Kidney Disease Improvement In Research and Treatment Act Reintroduced in Congress

Healthcare Law Update

Chronic Kidney Disease Improvement In Research and Treatment Act Reintroduced in Congress

John D. Fanburg,
Managing Member & Chair, Healthcare

Edward Hilzenrath
Member, Healthcare

Vanessa Coleman
Associate, Healthcare

BRACH | EICHLER^{LLC}
Counsellors at Law

8/30/2023

The Chronic Kidney Disease Improvement in Research and Treatment Act ([H.R. 5027](#)) was reintroduced on July 27, 2023 in the U.S. House of Representatives.

The proposed legislation would bolster initiatives for preventing Chronic Kidney Disease (CKD) by guaranteeing appropriate reimbursement for quality care. It would enhance patient access to cutting-edge drugs, technology, and advancements in kidney care. The proposed legislation includes provisions to enhance CKD screening through Medicare's annual wellness benefit, provide education resources in dialysis facilities, encourage innovation by requiring long-term payment pathways for new medical advancements, and address dialysis infrastructure and workforce challenges. Additionally, it would widen patient options and coverage by ensuring access to Medigap policies for those with kidney failure.

[Click Here to read the entire August 2023 Healthcare Law Update now!](#)

For more information, contact:

John D. Fanburg, Chair | 973.403.3107 | jfanburg@bracheichler.com

Edward Hilzenrath | 973.403.3114 | ehilzenrath@bracheichler.com

Vanessa Coleman | 973.364.5208 | vcoleman@bracheichler.com